Abstract
Background: This study investigates the interplay between ferritin heavy chain (FHC), p53, and systemic oxidative stress in melanoma patients. Methods: Patients (57 enrolled, 49 analyzed for immunohistochemistry) and tumor samples were categorized into three groups: low metastasis risk (cutaneous melanoma, Breslow thickness < 2 mm), high metastasis risk (Breslow > 2 mm), and metastatic melanoma. Systemic oxidative stress was evaluated via erythrocyte lipid peroxidation, while serum ferritin heavy and light chain (FHC and FLC, respectively) levels were measured using ELISA. Tumor p53 expression and 3-nitrotyrosine (3-NT) occurrence were analyzed via immunohistochemistry. Results: Serum FHC levels and the FHC:FLC ratio were elevated in melanoma patients compared to controls, with the highest and significant FHC increases seen in the high-risk (>2 mm) and metastatic groups. This increase aligned with elevated systemic oxidative stress parameters. While FHC and 3-NT were expressed consistently across all tumor stages, p53 expression was significantly higher in the metastatic group than in the low-risk group. Conclusions: Patients with thick cutaneous melanomas (>2 mm) and metastatic disease share common biological processes, highlighting a significant interplay between FHC, systemic oxidative stress, and p53 expression in melanoma progression.